Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Folia Histochemica et Cytobiologica
MENU
Shortcuts Submit an article Author Guidelines Ahead of Print Reviewers 2023 Editorial Board

open access

Vol 58, No 2 (2020)
Original paper
Submitted: 2019-12-25
Accepted: 2020-06-03
Published online: 2020-06-18
View PDF Download PDF file
Get Citation

Bisdemethoxycurcumin exerts a cell-protective effect via JAK2/STAT3 signaling in a rotenone-induced Parkinson’s disease model in vitro

Duanqun He12, Shuangxi Chen1, Zijian Xiao1, Heng Wu1, Guijuan Zhou1, Chenlin Xu1, Yunqian Chang1, Yihui Li1, Gang Wang3, Ming Xie1
DOI: 10.5603/FHC.a2020.0011
·
Pubmed: 32557525
·
Folia Histochem Cytobiol 2020;58(2):127-134.
Affiliations
  1. The First Affiliated Hospital, University of South China, Hengyang, Hunan 421001, PR China
  2. Shenzhen Baoan People’s Hospital (Group), The Second People’s Hospital, Shenzhen, Guangdong 518101, China
  3. Department of Rehabilitation, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, PR China

open access

Vol 58, No 2 (2020)
ORIGINAL PAPERS
Submitted: 2019-12-25
Accepted: 2020-06-03
Published online: 2020-06-18

Abstract

Introduction. Oxidative stress and cell apoptosis have both been suggested to be closely associated with the pathogenesis of Parkinson’s disease (PD). Previously, bisdemethoxycurcumin (BDMC) has been shown to exhibit several desirable characteristics as a candidate neuroprotective agent, including antioxidant and anti-inflammatory activities in the nervous system. However, whether BDMC can exert cell-protective roles in an in vitro model of PD remains unknown.

Material and methods. SH-SY5Y cells were pretreated with BDMC, with or without AG490 and SI-201, for 30 min, followed by a co-incubation with rotenone for 24 h. Subsequently, a cell viability assay and western blotting was performed, and SOD and GSH activities were analyzed.

Results. The results revealed that the pretreatment with BDMC enhanced the cell survival, antioxidative stress capacity and the phosphorylation levels of JAK/STAT3 in SH-SY5Y cells treated with rotenone. However, following the incubation with AG490 and SI-201, inhibitors of the JAK/STAT3 signaling pathway, BDMC was unable to exert cell-protective roles in SH-SY5Y cells treated with rotenone.

Conclusions. In conclusion, the results suggested that BDMC may exert a cell-protective role in SH-SY5Y cells in vitro via JAK2/STAT3 signaling, thus suggesting the possible application of BDMC for the treatment of neurodegenerative diseases related to JAK2/STAT3 signaling.

Abstract

Introduction. Oxidative stress and cell apoptosis have both been suggested to be closely associated with the pathogenesis of Parkinson’s disease (PD). Previously, bisdemethoxycurcumin (BDMC) has been shown to exhibit several desirable characteristics as a candidate neuroprotective agent, including antioxidant and anti-inflammatory activities in the nervous system. However, whether BDMC can exert cell-protective roles in an in vitro model of PD remains unknown.

Material and methods. SH-SY5Y cells were pretreated with BDMC, with or without AG490 and SI-201, for 30 min, followed by a co-incubation with rotenone for 24 h. Subsequently, a cell viability assay and western blotting was performed, and SOD and GSH activities were analyzed.

Results. The results revealed that the pretreatment with BDMC enhanced the cell survival, antioxidative stress capacity and the phosphorylation levels of JAK/STAT3 in SH-SY5Y cells treated with rotenone. However, following the incubation with AG490 and SI-201, inhibitors of the JAK/STAT3 signaling pathway, BDMC was unable to exert cell-protective roles in SH-SY5Y cells treated with rotenone.

Conclusions. In conclusion, the results suggested that BDMC may exert a cell-protective role in SH-SY5Y cells in vitro via JAK2/STAT3 signaling, thus suggesting the possible application of BDMC for the treatment of neurodegenerative diseases related to JAK2/STAT3 signaling.

Full Text:

View PDF Download PDF file
Get Citation

Keywords

oxidative stress; rotenone; SH-SY5Y cells; bisdemethoxycurcumin (BDMC); JAK/STAT3

About this article
Title

Bisdemethoxycurcumin exerts a cell-protective effect via JAK2/STAT3 signaling in a rotenone-induced Parkinson’s disease model in vitro

Journal

Folia Histochemica et Cytobiologica

Issue

Vol 58, No 2 (2020)

Article type

Original paper

Pages

127-134

Published online

2020-06-18

Page views

2038

Article views/downloads

1176

DOI

10.5603/FHC.a2020.0011

Pubmed

32557525

Bibliographic record

Folia Histochem Cytobiol 2020;58(2):127-134.

Keywords

oxidative stress
rotenone
SH-SY5Y cells
bisdemethoxycurcumin (BDMC)
JAK/STAT3

Authors

Duanqun He
Shuangxi Chen
Zijian Xiao
Heng Wu
Guijuan Zhou
Chenlin Xu
Yunqian Chang
Yihui Li
Gang Wang
Ming Xie

References (36)
  1. Cao Xu, Cao L, Ding L, et al. A New Hope for a Devastating Disease: Hydrogen Sulfide in Parkinson's Disease. Mol Neurobiol. 2018; 55(5): 3789–3799.
    CrossRefPubMed
  2. Keeney PM, Xie J, Capaldi RA, et al. Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J Neurosci. 2006; 26(19): 5256–5264.
    CrossRefPubMed
  3. Chaudhuri K, Schapira A. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. The Lancet Neurology. 2009; 8(5): 464–474.
    CrossRef
  4. Xia R, Mao ZH. Progression of motor symptoms in Parkinson's disease. Neurosci Bull. 2012; 28(1): 39–48.
    CrossRefPubMed
  5. Mattson MP. Apoptosis in neurodegenerative disorders. Nat Rev Mol Cell Biol. 2000; 1(2): 120–129.
    CrossRefPubMed
  6. Onyango IG. Mitochondrial dysfunction and oxidative stress in Parkinson's disease. Neurochem Res. 2008; 33(3): 589–597.
    CrossRefPubMed
  7. Youn JK, Kim DW, Kim ST, et al. PEP-1-HO-1 prevents MPTP-induced degeneration of dopaminergic neurons in a Parkinson's disease mouse model. BMB Rep. 2014; 47(10): 569–574.
    CrossRefPubMed
  8. Gagliardi S, Ghirmai S, Abel KJ, et al. Evaluation in vitro of synthetic curcumins as agents promoting monocytic gene expression related to β-amyloid clearance. Chem Res Toxicol. 2012; 25(1): 101–112.
    CrossRefPubMed
  9. Sandur SK, Pandey MK, Sung B, et al. Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanism. Carcinogenesis. 2007; 28(8): 1765–1773.
    CrossRefPubMed
  10. Ramezani M, Hatamipour M, Sahebkar A. Promising anti-tumor properties of bisdemethoxycurcumin: A naturally occurring curcumin analogue. J Cell Physiol. 2018; 233(2): 880–887.
    CrossRefPubMed
  11. Basile V, Ferrari E, Lazzari S, et al. Curcumin derivatives: molecular basis of their anti-cancer activity. Biochem Pharmacol. 2009; 78(10): 1305–1315.
    CrossRefPubMed
  12. Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol. 2003; 53 Suppl 3: S26–36; discussion S36.
    CrossRefPubMed
  13. Reynolds A, Laurie C, Mosley RL, et al. Oxidative Stress and the Pathogenesis of Neurodegenerative Disorders. Int Rev Neurobiol. 2007: 297–325.
    CrossRefPubMed
  14. La Fortezza M, Schenk M, Cosolo A, et al. JAK/STAT signalling mediates cell survival in response to tissue stress. Development. 2016; 143(16): 2907–2919.
    CrossRefPubMed
  15. Hoffmann CJ, Harms U, Rex A, et al. Vascular signal transducer and activator of transcription-3 promotes angiogenesis and neuroplasticity long-term after stroke. Circulation. 2015; 131(20): 1772–1782.
    CrossRefPubMed
  16. Eum WS, Shin MJ, Lee CH, et al. Neuroprotective effects of Tat-ATOX1 protein against MPP-induced SH-SY5Y cell deaths and in MPTP-induced mouse model of Parkinson's disease. Biochimie. 2019; 156: 158–168.
    CrossRefPubMed
  17. Park SI, Lee EH, Kim SoRa, et al. Anti-apoptotic effects of Curcuma longa L. extract and its curcuminoids against blue light-induced cytotoxicity in A2E-laden human retinal pigment epithelial cells. J Pharm Pharmacol. 2017; 69(3): 334–340.
    CrossRefPubMed
  18. Im JH, Yeo InJ, Hwang CJu, et al. PEGylated Erythropoietin Protects against Brain Injury in the MCAO-Induced Stroke Model by Blocking NF-κB Activation. Biomol Ther (Seoul). 2020; 28(2): 152–162.
    CrossRefPubMed
  19. Chen S, Hou Y, Zhao Z, et al. Neuregulin-1 Accelerates Functional Motor Recovery by Improving Motoneuron Survival After Brachial Plexus Root Avulsion in Mice. Neuroscience. 2019; 404: 510–518.
    CrossRefPubMed
  20. Li J, Chen S, Zhao Z, et al. Effect of VEGF on Inflammatory Regulation, Neural Survival, and Functional Improvement in Rats following a Complete Spinal Cord Transection. Front Cell Neurosci. 2017; 11: 381.
    CrossRefPubMed
  21. Chen SX, He JH, Mi YJ, et al. A mimetic peptide of α2,6-sialyllactose promotes neuritogenesis. Neural Regen Res. 2020; 15(6): 1058–1065.
    CrossRefPubMed
  22. Yuhai GU, Zhen Z. Significance of the changes occurring in the levels of interleukins, SOD and MDA in rat pulmonary tissue following exposure to different altitudes and exposure times. Exp Ther Med. 2015; 10(3): 915–920.
    CrossRefPubMed
  23. Mao GX, Zheng LD, Cao YB, et al. Antiaging effect of pine pollen in human diploid fibroblasts and in a mouse model induced by D-galactose. Oxid Med Cell Longev. 2012; 2012: 750963.
    CrossRefPubMed
  24. Zhang Bo, Chen Na, Chen H, et al. The critical role of redox homeostasis in shikonin-induced HL-60 cell differentiation via unique modulation of the Nrf2/ARE pathway. Oxid Med Cell Longev. 2012; 2012: 781516.
    CrossRefPubMed
  25. Xu J, Hu C, Chen S, et al. Neuregulin-1 protects mouse cerebellum against oxidative stress and neuroinflammation. Brain Res. 2017; 1670: 32–43.
    CrossRefPubMed
  26. Chen Sx, Hu Cl, Liao Yh, et al. L1 modulates PKD1 phosphorylation in cerebellar granule neurons. Neurosci Lett. 2015; 584: 331–336.
    CrossRefPubMed
  27. Jiang Q, Chen S, Hu C, et al. Neuregulin-1 (Nrg1) signaling has a preventive role and is altered in the frontal cortex under the pathological conditions of Alzheimer's disease. Mol Med Rep. 2016; 14(3): 2614–2624.
    CrossRefPubMed
  28. Vogt Weisenhorn DM, Giesert F, Wurst W. Diversity matters - heterogeneity of dopaminergic neurons in the ventral mesencephalon and its relation to Parkinson's Disease. J Neurochem. 2016; 139 Suppl 1: 8–26.
    CrossRefPubMed
  29. Olanow CW, Schapira AHV, Agid Y. Neuroprotection for Parkinson's disease: prospects and promises. Ann Neurol. 2003; 53 Suppl 3: S1–S2.
    CrossRefPubMed
  30. Xie Hr, Hu Ls, Li Gy. SH-SY5Y human neuroblastoma cell line: in vitro cell model of dopaminergic neurons in Parkinson's disease. Chin Med J (Engl). 2010; 123(8): 1086–1092.
    PubMed
  31. Xicoy H, Wieringa Bé, Martens GJM. The SH-SY5Y cell line in Parkinson's disease research: a systematic review. Mol Neurodegener. 2017; 12(1): 10.
    CrossRefPubMed
  32. Morales-Garcia JA, Aguilar-Morante D, Hernandez-Encinas E, et al. Silencing phosphodiesterase 7B gene by lentiviral-shRNA interference attenuates neurodegeneration and motor deficits in hemiparkinsonian mice. Neurobiol Aging. 2015; 36(2): 1160–1173.
    CrossRefPubMed
  33. Dexter DT, Jenner P. Parkinson disease: from pathology to molecular disease mechanisms. Free Radic Biol Med. 2013; 62: 132–144.
    CrossRefPubMed
  34. Agrawal S, Singh A, Tripathi P, et al. Cypermethrin-induced nigrostriatal dopaminergic neurodegeneration alters the mitochondrial function: a proteomics study. Mol Neurobiol. 2015; 51(2): 448–465.
    CrossRefPubMed
  35. Lee HJ, Shin SY, Choi C, et al. Formation and removal of alpha-synuclein aggregates in cells exposed to mitochondrial inhibitors. J Biol Chem. 2002; 277(7): 5411–5417.
    CrossRefPubMed
  36. Zheng Wx, Wang F, Cao Xl, et al. Baicalin protects PC-12 cells from oxidative stress induced by hydrogen peroxide via anti-apoptotic effects. Brain Inj. 2014; 28(2): 227–234.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl